Summary of Key Points Core Viewpoint The article provides an overview of the recent activities in the Hong Kong stock market, highlighting the number of companies that have submitted listing applications, those that have passed the hearing process, and new stocks that have been listed. Group 1: Companies Submitting Listing Applications - A total of 30 companies submitted listing applications to the Hong Kong Stock Exchange during the week from September 29 to October 5 [1] - Notable companies include: - Yantai Lannacheng Biotechnology Co., Ltd., a clinical-stage biotech company focused on radiopharmaceuticals for cancer treatment, reported revenues of approximately 1.027 million RMB for 2023 and a loss of about 112 million RMB [2][3] - XGIMI Technology Co., Ltd., the world's largest consumer-grade projector brand by revenue, reported revenues of approximately 4.22 billion RMB for 2022 and a profit of about 501 million RMB [2][3] - WeDoctor Holdings Limited, a leading digital health service provider in China, reported revenues of 1.368 billion RMB for 2022 and a loss of 909 million RMB [4][5] - Puyuan Precision Electronics Co., Ltd., the largest electronic measurement instrument supplier in China, reported revenues of approximately 631 million RMB for 2022 and a profit of about 92.5 million RMB [5][6] - Shenzhen Huanchuang Technology Co., Ltd., a leader in high-precision spatial perception solutions, reported a market share of over 50% in the laser radar products for robotic vacuum cleaners [6] Group 2: Companies Passing Hearing Process - Four companies passed the listing hearing this week: - Jushuitan Group Co., Ltd., the largest e-commerce SaaS ERP provider in China, reported revenues of approximately 523 million RMB for 2022 and a loss of about 507 million RMB [30][31] - Fujian Haixi New Drug Creation Co., Ltd., a commercial-stage pharmaceutical company, reported revenues of approximately 212 million RMB for 2022 and a profit of about 69 million RMB [30][31] - Beijing Tongrentang Medical Investment Co., Ltd., the largest non-public Chinese hospital group by market share, reported revenues of approximately 911 million RMB for 2022 and a loss of about 9.23 million RMB [32] - Beijing Yunji Technology Co., Ltd., a robotics service provider, reported revenues of approximately 161 million RMB for 2022 and a loss of about 365 million RMB [32][33] Group 3: New Stocks Listed - Three new stocks were listed on September 30: - Zijin Gold International, which saw a significant increase in market value, surpassing 350 billion HKD [35] - Xipuni, which had an oversubscription rate of 2505.9 times during its public offering [35] - Botai Che Lian, which also experienced a notable increase in stock price [35]

Core Insights - XGIMI Technology is focused on the research, production, and sales of various consumer-grade, automotive-grade, and engineering-grade smart projection products, with a global presence in over 100 countries and regions, and more than 6,000 offline points of sale [4] - The company has maintained its position as the top seller in China's projection industry for seven consecutive years since 2018 and has been the revenue leader in the domestic market for five years, holding approximately 30.2% market share in 2024 [4] - XGIMI has developed a strong capability base in optical technology and user interaction, allowing it to expand its product offerings to higher-demand automotive and engineering-grade projection products, with its automotive projection business already in mass production [4] Business Model - In China, XGIMI provides internet value-added services through its GMUI platform, allowing customers to access audio-visual content and various applications, sharing a portion of user payments with application developers [5] - Internationally, XGIMI collaborates with game developers to distribute games on third-party platforms and shares revenue according to pre-agreed ratios, also partnering with streaming platforms to facilitate access for overseas users [5] Financial Performance - For the fiscal years 2022 to 2025, XGIMI's revenues were approximately CNY 42.20 billion, CNY 35.52 billion, CNY 34.00 billion, and CNY 16.23 billion respectively, with net profits of CNY 5.01 billion, CNY 1.20 billion, CNY 1.20 billion, and CNY 0.88 billion [5] - The gross profit margin has shown fluctuations, with gross profits of CNY 1.48 billion (35.0%), CNY 1.06 billion (29.8%), CNY 1.03 billion (30.3%), and CNY 445.51 million (27.9%) over the same periods [8]